Caris Life Sciences Reports Preliminary Q4 and Full Year 2025 Revenue Growth of 116% and 94% Respectively

summarizeSummary

Caris Life Sciences announced strong preliminary unaudited financial results for Q4 and full year 2025, with significant revenue growth and an improved cash position, ahead of its J.P. Morgan Healthcare Conference presentation.

check_boxKey Events

• Strong Full Year Revenue Growth

  Preliminary unaudited total revenue for 2025 reached approximately $800 million, marking a 94% increase from 2024.

• Exceptional Q4 Performance

  Fourth quarter 2025 preliminary total revenue was approximately $281 million, an increase of 116% compared to the same period in 2024.

• Healthy Cash Position

  Cash, cash equivalents, restricted cash, and marketable securities increased by approximately $43 million from Q3 2025, totaling $802 million as of December 31, 2025.

• J.P. Morgan Healthcare Conference Presentation

  The company will present these results and additional business updates at the 2026 J.P. Morgan Healthcare Conference.

auto_awesomeAnalysis

Caris Life Sciences reported robust preliminary financial results for the fourth quarter and full year 2025, highlighted by substantial revenue growth. The company achieved approximately $800 million in total revenue for the full year, representing a 94% increase, and $281 million for Q4, a 116% increase. This strong performance, particularly in molecular profiling services, underscores the company's operational momentum and the CEO's characterization of 2025 as a "breakthrough year." Additionally, the company's cash, cash equivalents, restricted cash, and marketable securities increased by $43 million to approximately $802 million, indicating a healthy financial position. Investors should note these are preliminary figures, but the significant growth trajectory is a strong positive signal.